Compare Intel Corp (INTC) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Intel Corp trades at $109.26 (market cap $597.96B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B). The key difference: Intel Corp is far larger — about 10.3× Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| INTC | TAK | |
|---|---|---|
Market Cap | $597.96B | $58.16B |
Volume | 82,330,296 | 2,467,530 |
Sector | Technology | Health |
52-Week High | $140.94 | $19.05 |
52-Week Low | $33.62 | $13.23 |
Typical Hold Time | 116 Days | 0 Days |
Enterprise Value | $618.77B | $86.04B |
Dividend Yield | 2.24% | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $107.08, down 4.82% today but maintains a bullish technical outlook with strong 2026 performance. The stock has surged over 220% year-to-date, driven by AI momentum and foundry growth. Recent earnings beats and High-NA chipmaking progress signal operational improvement, though negative profitability metrics and high valuations present challenges. Technical indicators show bullish momentum with key support at $109.
Intel's turnaround story shows promise with foundry revenue growth and government support, but faces execution risks against dominant competitors. The stock trades near analyst consensus target of $111.72, offering modest upside potential. Key risks include competitive pressures, margin challenges, and high debt levels that could limit near-term shareholder returns.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
